A recent ruling by a US trade tribunal has favored Apple in its ongoing legal battle with medtech company Masimo. The tribunal dismissed Masimo's request to reinstate an import ban on Apple Watches, a decision that allows Apple to continue selling its products without restrictions.
The US International Trade Commission (ITC) concluded that Apple’s redesigned watches do not infringe on Masimo's patents concerning blood-oxygen monitoring technology. This ruling came after the ITC chose not to review a preliminary decision made in March.
Background of the Dispute
Masimo, which is owned by Danaher, has been pursuing legal action against Apple for several years. The company has accused Apple of unlawfully acquiring its technology by hiring away key employees. In December 2023, the ITC had initially blocked imports of Apple’s Series 9 and Ultra 2 smartwatches, ruling that they violated Masimo's patents.
Apple's Response and Adaptations
To circumvent the import ban, Apple removed the blood-oxygen reading feature from its watches. However, the company later reintroduced an updated version of this technology in August, which was approved by US Customs and Border Protection. The new feature displays health data on connected devices like the iPhone, rather than directly on the watch.
Next Steps for Masimo
Masimo retains the option to appeal the ITC's decision to the US Court of Appeals for the Federal Circuit. Additionally, the company has filed a separate lawsuit against Customs regarding the approval of the redesigned watches.
Ongoing Legal Challenges
In a related matter, Masimo has also taken legal action against Apple in California, alleging patent infringement and trade-secret theft. In a notable trial last November, Masimo was awarded $634 million, a verdict that Apple has indicated it plans to appeal.
Conclusion
This ruling marks a significant victory for Apple, allowing the company to maintain its market presence without the threat of an import ban. The ongoing legal disputes between Apple and Masimo highlight the complexities of intellectual property rights in the tech industry.
